Accord Farmacutica Ltda.

Accord Farmacêutica Ltda. is a Brazilian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in São Paulo, Brazil, the company operates under the CNPJ number 64.171.697/0001-46. Its primary focus is on sourcing and distributing oncology, hematology, and critical care medications, aligning with the therapeutic areas of its parent company, Intas Pharmaceuticals Limited. (econodata.com.br)

As a key player in Brazil's pharmaceutical supply chain, Accord Farmacêutica Ltda. serves as a critical link between international manufacturers and the Brazilian healthcare system. By importing and distributing a diverse range of pharmaceutical products, the company ensures the availability of essential medications across the country, contributing to the overall health infrastructure. Its strategic partnerships and efficient distribution network enable it to meet the growing demand for specialized treatments in Brazil.

Accord Farmacêutica Ltda. maintains a centralized distribution model from its São Paulo headquarters, facilitating efficient logistics and inventory management. While specific warehouse locations are not publicly disclosed, the company's strategic position in São Paulo allows for effective distribution throughout Brazil. This centralization enables timely delivery of pharmaceutical products to various regions, ensuring consistent supply to healthcare providers nationwide.

The company's logistics capabilities are enhanced by its affiliation with Intas Pharmaceuticals Limited, which operates multiple certified manufacturing facilities globally. This affiliation ensures a steady supply of high-quality pharmaceutical products, leveraging Intas's established distribution channels and expertise in international logistics. Accord Farmacêutica Ltda.'s distribution network is designed to meet the diverse needs of the Brazilian market, ensuring that critical medications reach healthcare facilities and patients promptly.

Accord Farmacêutica Ltda. functions primarily as a pharmaceutical importer and wholesaler within Brazil's healthcare sector. By sourcing finished pharmaceutical formulations from international manufacturers, particularly from India, the company plays a pivotal role in introducing and distributing a wide array of medications to the Brazilian market. This includes treatments in oncology, hematology, and critical care, addressing the specific therapeutic needs of the Brazilian population.

In addition to its importing and wholesaling activities, Accord Farmacêutica Ltda. collaborates with various stakeholders in the healthcare system, including hospitals, clinics, and government agencies. These collaborations ensure that essential medications are accessible to patients across Brazil, thereby contributing to the overall improvement of public health. The company's strategic partnerships and efficient distribution channels underscore its significant position in the pharmaceutical supply chain.

Accord Farmacêutica Ltda. exhibits a high degree of sourcing concentration, with all its pharmaceutical imports originating from a single supplier: Intas Pharmaceuticals Limited. This exclusive sourcing strategy has resulted in a total import value of $3.3 million USD over 88 shipments, encompassing 103 unique formulations across five products in three therapeutic categories. The top five imported products include Paclitaxel ($1.1 million, 1.4% share), Mycophenolate ($950K, 0.3% share), Cytarabine ($795K, 4.3% share), Topotecan ($300K, 5.3% share), and Cisplatin ($129K, 1.0% share).

This single-source dependency presents both strategic advantages and potential risks. On the positive side, a focused relationship with Intas Pharmaceuticals Limited may lead to favorable pricing, consistent product quality, and streamlined logistics. However, the lack of supplier diversification could expose Accord Farmacêutica Ltda. to supply chain disruptions in the event of issues such as production delays, regulatory challenges, or geopolitical tensions affecting the supplier. The company's reliance on a single supplier underscores the importance of maintaining a robust and resilient supply chain to mitigate potential risks.

Accord Farmacêutica Ltda.'s supply chain resilience is closely tied to its exclusive partnership with Intas Pharmaceuticals Limited. This relationship ensures access to a diverse portfolio of 103 unique pharmaceutical formulations, encompassing five products across three therapeutic categories: Oncology (38.2%), Advanced Oncology (33.1%), and Immunosuppressants (28.7%). The comprehensive range of products indicates a well-established and reliable supply chain.

However, the absence of backup suppliers introduces potential vulnerabilities. In the event of disruptions affecting Intas Pharmaceuticals Limited, such as production issues or regulatory challenges, Accord Farmacêutica Ltda. may face challenges in sourcing alternative products. To enhance supply chain resilience, it would be prudent for Accord Farmacêutica Ltda. to consider diversifying its supplier base and establishing contingency plans to mitigate potential risks.

Accord Farmacêutica Ltda.'s sourcing pattern, characterized by exclusive reliance on Intas Pharmaceuticals Limited, has significant strategic implications. For Accord Farmacêutica Ltda., this concentrated sourcing strategy may lead to favorable terms, including competitive pricing and consistent product quality. The strong partnership with Intas Pharmaceuticals Limited can also facilitate streamlined logistics and efficient supply chain management.

For Indian exporters seeking to become alternative suppliers to Accord Farmacêutica Ltda., understanding the company's current sourcing dynamics is crucial. While the existing relationship with Intas Pharmaceuticals Limited is strong, there may be opportunities to introduce complementary products or offer competitive advantages in terms of pricing, quality, or innovation. Engaging in strategic discussions and demonstrating value propositions aligned with Accord Farmacêutica Ltda.'s needs could pave the way for potential collaborations.

In Brazil, the primary regulatory authority overseeing pharmaceutical imports is the National Health Surveillance Agency (ANVISA). ANVISA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Brazilian market. The agency establishes and enforces regulations governing the importation, registration, and commercialization of pharmaceutical products.

Key legislation governing pharmaceutical imports includes the Brazilian Health Regulatory Agency Law (Law No. 9,782/1999) and the Health Surveillance System Law (Law No. 13,410/2016). These laws outline the procedures for product registration, import licensing, and compliance with Good Manufacturing Practices (GMP). For Indian generics to be marketed in Brazil, they must undergo a registration process with ANVISA, demonstrating compliance with Brazilian standards and regulations.

Import licensing in Brazil requires that pharmaceutical products be registered with ANVISA before they can be imported and marketed. This process involves submitting comprehensive documentation, including evidence of GMP compliance, product specifications, and clinical data. ANVISA recognizes GMP certifications from reputable international bodies, such as the European Medicines Agency (EMA), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian manufacturers seeking to export generics to Brazil must ensure their facilities hold valid GMP certifications from these recognized organizations.

Additionally, companies must obtain wholesale distribution authorization from ANVISA, which involves demonstrating compliance with storage, handling, and distribution standards. This authorization is essential for entities like Accord Farmacêutica Ltda. to legally distribute pharmaceutical products within Brazil.

Pharmaceutical products imported into Brazil are subject to batch testing and stability requirements to ensure their safety and efficacy. ANVISA mandates that imported drugs undergo quality control procedures, including testing for purity, potency, and stability. These tests are conducted to verify that the products meet the established standards and remain effective throughout their shelf life.

Labeling requirements stipulate that all information be presented in Portuguese, including product name, dosage form, strength, indications, and instructions for use. Serialization mandates are also in place to enhance traceability and prevent counterfeit products from entering the market. These measures are part of Brazil's efforts to maintain the integrity of its pharmaceutical supply chain and protect public health.

Between 2024 and 2026, Brazil implemented several regulatory changes affecting pharmaceutical imports. ANVISA introduced stricter guidelines for product registration, emphasizing the need for comprehensive clinical data and enhanced pharmacovigilance reporting. Additionally, there was an increased focus on the recognition of international GMP certifications, with ANVISA updating its list of accepted certifying bodies to include more global organizations. These changes aim to strengthen the quality and safety of pharmaceutical products available in Brazil.

Accord Farmacêutica Ltda.'s focus on importing products in the oncology, hematology, and critical care therapeutic areas aligns with the growing demand for specialized treatments in Brazil. The Brazilian healthcare system faces challenges in providing access to advanced therapies, making these areas critical for patient care. By sourcing medications in these categories, Accord Farmacêutica Ltda. addresses unmet medical needs and contributes to improving health outcomes.

The market demand for these imports is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical research leading to new treatment options. Accord Farmacêutica Ltda.'s strategic product selection positions it to meet these evolving healthcare needs effectively.